<DOC>
	<DOCNO>NCT02279498</DOCNO>
	<brief_summary>Liprotamase powder non-porcine , soluble stable mixture three digestive enzyme include lipase , protease , amylase . The purpose present study provide additional efficacy safety data compare approve , porcine-derived , enterically-coated encapsulate pancreatic enzyme replacement therapy . The primary efficacy endpoint study comparative efficacy measure change coefficient fat absorption ( CFA ) Cystic Fibrosis patient exocrine pancreatic insufficiency ( EPI ) . Liprotamase stable stomach digestive fluid allow administration variety convenient formulation number food without enteric coating .</brief_summary>
	<brief_title>SOLUTION : Study Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Diagnosis Cystic Fibrosis base presentation , genotype and/or sweat chloride Fecal elastase &lt; 100 mcg/g stool Minimum Coefficient Fat ( CFA ) screen stable PERT therapy Good nutritional status History diagnosis fibrosing colonopathy Distal intestinal obstruction syndrome 6 month prior screen Receiving enteral tube feeding Chronic diarrheal illness unrelated pancreatic insufficiency Liver abnormality , liver lung transplant , significant bowel resection Forced expiratory volume 1 second ( FEV1 ) &lt; 30 %</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>